## Supplementary Materials:



**Supplementary Figure S1: Conditional** *Slc7a7* **gene deletion and effect on protein**. (a) Schematic representation of *Slc7a7* conditional strategy. First row represents wild-type murine Slc7a7 with open boxes for untranslated exons and black boxes for codifying exons. Exons 3 and 4 are flanked by loxP sequences (triangles) generating a conditional *Slc7a7* loxP, in which, after tamoxifen induction, an *in vivo* Cre-mediated excision occurs, leading to a non-functional protein (*Slc7a7*<sup>-/-</sup>); (b) Genotyping of control (*Slc7a7*<sup>+/+</sup>), *Slc7a7*<sup>loxP/+</sup> and *Slc7a7*<sup>loxP/loxP</sup> mice with or without Cre by multiplex PCR amplification of genomic DNA. Expected bands of 741 bp and 886bp are detected for the *Slc7a7*<sup>+</sup> and *Slc7a7*<sup>loxP</sup> alleles. Amplification of the Cre band is detected at 597 bp; (c) Schematic topology of y<sup>+</sup>LAT1 protein. Deleted region in the *Slc7a7*<sup>-/-</sup> mouse is depicted in gray and the epitope used to generate rabbit anti-mouse SLC7A7 antibody is showed in red.



**Supplementary Figure S2**. **Metabolic parameters and organ weights.** (a-c) Liver, kidney and gastrocnemius weight of control (black bars) and *Slc7a7*<sup>-/-</sup> (white bars) animals fed with an 8% of protein diet with or without citrulline supplementation; (d) amount of feces excreted in 24h; (e) water intake, in mL in 24h; (f) volume of urine excreted in 24h.



**Supplementary Figure S3. Glomerular filtration rate**. (a) Glomerular filtration rate was estimated using Equation 2 (see Supplementary equation 2) in control (black bars) and *Slc7a7*-<sup>*L*</sup> (white bars) mice; (**b-c**) Creatinine concentration ( $\mu$ M) in plasma and urine are also shown. In all cases, mice were analyzed after 7-10 days on an 8% protein diets with or without citrulline in drinking water. Data corresponds to the mean±SEM of 6 mice per group. Statistical significance \*p < 0.05 vs. control. #p<0.05, ##p<0.01 vs. citrulline treatment was analyzed using a Student's t-test.



**Supplementary Figure S4**. Oral gavage of 1g glucose/kg was performed in control (black squares) and *Slc7a7*-/- (white squares) animals. Glucose was measured before the oral gavage and at 5, 15 and 30 minutes after the glucose administration. Data corresponds to the mean±SEM of 6 mice per group.



**Supplementary Figure S5. PAP development**. Analysis of PAP development compared to severity of LPI measured as body weight lost at the day of sacrifice. Data corresponds to the mean $\pm$ SEM of 15 control (n=7 treated with citrulline and n=8 without citrulline treatment) and 20 *Slc7a7*<sup>-/-</sup> (n=10 treated with citrulline and n=10 not treated) mice. Statistical significance \*p < 0.05 vs. control was analyzed using a Student's t-test. Animals were on a low protein diet with or without citrulline supplementation for 15-55 days.

**Supplementary Table S1.** Amino acid concentration in plasma. Plasma concentrations ( $\mu$ M) were determined in mice with the indicated genotypes at 12 months of age and after 10 days on an 8% protein diet. Data corresponds to the mean±SEM of 6 mice per group. Statistical significance \*p < 0.05, \*\*p<0.01, \*\*\*p<0.001, \*\*\*\*p<0.0001 vs. control. #p<0.05, ##p<0.01, ###p<0.001 vs. citrulline supplementation was analyzed using a Student's t-test. Amino acids are designated with the three-letter code.

Amino acid	Co	ol	SIc7a7 <sup>-/-</sup>				Co	ol + C	it	Slc7a7 ⁻/-+ Cit					
THR	119.3	±	14.5	181.9	±	1.5	**	254.2	±	19.5	###	189.7	±	27.2	
SER	84.5	±	6.2	134.3	±	12.5	**	186.6	±	13.5		144.6	±	16.5	
ASN	34.5	±	2.3	56.0	±	7.4	*	50.9	±	5.2	#	61.4	±	5.2	
GLN	470.5	±	44.4	1005	±	90.1	***	591.4	±	93.9	###	839.5	±	112.7	
GLY	144.4	±	19.9	244.9	±	35.3	*	268.6	±	25.6	##	210.7	±	11.9	
ALA	279.2	±	23.7	528.5	±	76.3	**	747.8	±	98.9	###	451.4	±	53.8	*
CTR	44.4	±	4.4	84.1	±	11.2	**	86.1	±	6.8	###	119.2	±	11.1	* #
VAL	136.4	±	18.3	158.4	±	15.1		190.8	±	11.0	#	135.5	±	11.0	**
MET	37.4	±	3.4	62.0	±	6.2	**	66.1	±	8.5	#	61.1	±	9.2	
ILE	53.2	±	7.0	56.8	±	6.1		84.2	±	4.1	##	53.5	±	2.3	****
LEU	97.3	±	17.0	113.3	±	11.7		132.5	±	7.5		96.1	±	6.5	**
HIS	50.8	±	6.7	90.0	±	10.8	*	85.7	±	9.0	#	62.0	±	4.9	* #
TVP	38.8		24	58.7	-	5.8	*	53.0		1 0	##	71.2		83	
	10.0	T T	2.4 6.1	75.0	т т	J.0	*	70.6	T	1.9	##	59.2	T	20	* #
FIL	49.0		0.1	15.9		1.1		79.0		0.0	#	J0.2	I	2.9	#
PRO	57.6	±	2.7	96.7	±	7.6	***	129.0	±	27.5	#	92.1	±	8.2	
ASP	17.1	±	1.2	17.1	±	3.5		34.6	±	1.4		19.6	±	4.8	
GLU	52.1	±	7.9	33.1	±	3.3		65.4	±	20.6		56.80	±	11.1	
ARG	171	<b>_</b>	6.8	11 /	<b>–</b>	3.6	***	72.0	<b>_</b>	17 1		21.1	+	53	* #
	32 /	T	1.6	33.7	T	7.0		104.5	T	16.2	##	31.1	T	3.0	**
	464.6	т +	82.2	189.2	т +	20.1	**	321 0	т +	84	<del>##</del>	159.2	т +	15.6	****
LIU	-04.0	Т	02.2	103.5	Ξ.	20.1		021.9	-	0.4		103.2	-	10.0	

**Supplementary Table S2. Excretion of amino acids in urine.** Excretion, expressed as nmols of the indicated amino acid per gram of body weight in a 24-hour sample, was assessed in mice with the indicated genotypes at 12 months of age and after 7-10 days on an 80% protein with or without citrulline (Cit) supplementation. Data corresponds to the mean±SEM of 6 mice per group. Statistical significance \*p < 0.05, \*\*p<0.01, \*\*\*p<0.001 vs. control. #p<0.05, ##p<0.01, ###p<0.001 vs. citrulline supplementation was analyzed using a Student's t-test. Amino acids are designated with the three-letter code.

Amino acid	Co	ontr	ntrol <i>SIc7a7</i> -/-						ontr	ol + Cit	S <i>l</i> c7a7 <sup>-/-</sup> + Cit				
THR	18.9	±	4.1	25.1	±	4.9		30.6	±	4.7	47.2	±	5.8	#	
SER	4.3	±	0.4	5.6	±	1.0		4.9	±	0.8	8.7	±	1.3	*	
ASN	4.4	±	0.6	5.8	±	1.1		5.8	±	1.1	8.0	±	1.1		
GLN	15.8	±	1.3	116.2	±	30.0	**	24.8	±	8.8	328.9	±	69.8	** #	
GLY	15.0	±	2.1	10.3	±	1.9		17.2	±	1.3	12.7	±	1.2	*	
ALA	9.6	±	1.5	9.8	±	1.9		10.4	±	1.0	16.5	±	2.8		
CTR	8.5	±	1.6	13.0	±	5.7		8.6	±	2.0	92.2	±	20.0	**##	
VAL	4.2	±	0.6	4.3	±	1.4		4.1	±	0.7	5.7	±	0.9		
MET	9.9	±	1.7	22.8	±	4.6	*	15.7	±	4.3	46.9	±	7.9	**#	
ILE	1.3	±	0.2	1.3	±	0.7		2.1	±	0.4	2.7	±	0.4		
LEU	2.8	±	0.2	2.5	±	1.1		6.8	±	2.4	4.9	±	1.0		
HIS	1.9	±	0.2	4.9	±	1.4		3.0	±	0.5	14.4	±	18.4	** #	
TYR	34	+	0.5	3.6	+	10		51	+	0.5	10.3	+	1.6	** <del>##</del>	
DHE	27	±	0.0	2.0	±	0.6		3.7	±	0.5	37	-	0.4	#	
	2.1		0.5	2.0	Ξ	0.0	_	J.Z	I	0.0	5.1		0.4	#	
PRO	6.7	±	2.0	21.1	±	8.0		17.9	±	7.6	40.0	±	2.7		
ASP	2.6	±	0.6	2.5	±	1.9		2.5	±	0.4	4.0	±	1.8		
GLU	2.5	±	0.4	4.2	±	1.0		3.9	±	0.9	9.4	±	1.2	**##	
ARC	10	+	03	72.2	<u>т</u>	30.0	*	02	+	3.4	667.0	+	150.0	** <del>////</del>	
ORN	2.7	т +	0.5	64.7	т +	26.4	*	0.2	т +	1 1	260.6	т +	61.0	**#	
	2.1	т Т	0.5	04.7	т Т	20.4		7.5	т Т	0.9	16.6	T	01.0	π *** <del>###</del>	
LIS	9.3	Ŧ	0.6	9.5	Í	0.6		1.5	±	0.0	40.0	±	0.0	###	

**Supplementary Table S3: Renal clearance of amino acids**. Renal clearance (mL/24h·g body weight) was calculated in control and *Slc7a7<sup>-/-</sup>* mice at 12 months of age and after 7-10 days on an 8% protein diet with or without citrulline (Cit) supplementation. Data corresponds to the mean±SEM of 6 mice per group. Statistical significance \*p < 0.05, \*\*p<0.01, \*\*\*p<0.001 vs. control. #p<0.05, ##p<0.01 vs. citrulline supplementation was analyzed using a Student's t-test. Amino acids are designated with the three-letter code.

Amino acid	Co	ont	rol	SIc7a7-I-				Co	ont	rol + C	it	<i>Slc7a7⁻</i> + Cit			
THR	0.19	±	0.05	0.14	±	0.03		0.14	±	0.01		0.28	±	0.04	*#
SER	0.05	±	0.01	0.04	±	0.01		0.04	±	0.00		0.06	±	0.01	*
ASN	0.16	±	0.04	0.12	±	0.03		0.12	±	0.01		0.17	±	0.03	
GLN	0.03	±	0.00	0.11	±	0.03	*	0.03	±	0.00		0.42	±	0.09	**##
GLY	0.11	±	0.01	0.05	±	0.01	**	0.10	±	0.02		0.06	±	0.01	
ALA	0.03	±	0.00	0.02	±	0.00		0.02	±	0.00	##	0.03	±	0.00	*
CTR	0.19	±	0.02	0.10	±	0.03	*	0.11	±	0.02	#	0.76	±	0.14	**##
VAL	0.02	±	0.00	0.03	±	0.01		0.03	±	0.00	#	0.04	±	0.00	
MET	0.29	±	0.03	0.38	±	0.09		0.33	±	0.07		0.83	±	0.15	*#
ILE	0.03	±	0.01	0.03	±	0.01		0.04	±	0.01		0.04	±	0.01	
LEU	0.03	±	0.00	0.03	±	0.01		0.10	±	0.04		0.05	±	0.00	
HIS	0.03	±	0.00	0.06	±	0.01		0.05	±	0.00		0.23	±	0.05	**##
TVD	0.07		0.04	0.00		0.00		0.00		0.04		0.40		0.00	
IYR	0.07	±	0.01	0.06	±	0.02	_	0.09	±	0.01		0.13	±	0.03	
PHE	0.05	±	0.00	0.03	±	0.01		0.06	±	0.01		0.06	±	0.01	#
PRO	0.11	±	0.02	0.24	±	0.10		0.23	±	0.03		0.44	±	0.05	**
ASP	0.25	±	0.08	0.26	±	0.10		0.38	±	0.21		0.31	±	0.15	
GLU	0.09	±	0.00	0.08	±	0.02		0.10	±	0.01		0.16	±	0.03	
APC	0.04	4	0.00	1 20	-	7 22	**	0.10		0.05	#	27.22	-	0 7/	*#
ARG	0.04	I	0.00	4.30	Í	1.52	*	0.19	Ť	0.05	#	21.23	Í	0.74	#
ORN	0.07	±	0.01	3.20	±	1.41		0.07	±	0.02		9.42	±	2.91	
LYS	0.03	±	0.00	0.07	±	0.02	*	0.03	±	0.00		0.30	±	0.05	***##

**Supplementary Table S4: Tubular reabsorption of neutral and acidic amino acids.** The percentage of tubular reabsorption was estimated in control and *Slc7a7*-/- at 12 months of age and after 7-10 days on an 8% protein-content diet with (Cit) or without citrulline supplementation. Data corresponds to the mean±SEM of 6 mice per group. Statistical significance \*p<0.05, \*\*p<0.01, \*\*\*p<0.001 vs. control. #p<0.05, ##p<0.01 vs. citrulline supplementation was analyzed using a Student's t-test. Amino acids are designated with the three-letter code.

Amino acid	Co	ntr	ol		7a7- <sup>,,</sup>		Con	trol	+ Cit	Slo	Slc7a7⁻┘- + Cit			
THR	98.3	±	0.5	98.0	±	0.2		98.1	±	0.2	96.3	±	0.7	*#
SER	99.4	±	0.1	99.4	±	0.1		99.6	±	0.1	99.0	±	0.2	**
ASN	98.7	±	0.2	98.5	±	0.2		98.0	±	0.5	98.2	±	0.3	
GLN	99.7	±	0.1	97.8	±	0.3	****	99.5	±	0.1	94.4	±	1.3	**#
GLY	98.8	±	0.1	99.4	±	0.1	*	98.8	±	0.2	99.0	±	0.1	
ALA	99.6	±	0.1	99.6	±	0.1		99.7	±	0.1	99.4	±	0.1	**
CTR	98.1	±	0.3	97.1	±	0.3		98.5	±	0.3	86.3	±	4.0	*#
VAL	99.6	±	0.1	99.4	±	0.2		99.6	±	0.2	99.3	±	0.1	
MET	96.8	±	0.4	93.8	±	1.8	**	96.0	±	0.9	89.3	±	1.4	**#
ILE	99.7	±	0.1	99.1	±	0.2		99.6	±	0.1	99.7	±	0.1	#
LEU	99.7	±	0.1	99.8	±	1.0		98.9	±	0.5	99.1	±	0.2	#
HIS	99.6	±	0.1	98.7	±	0.2	*	99.4	±	0.1	96.1	±	1.0	**#
TYR	99.2	±	0.2	99.3	±	0.1		98.8	±	0.2	97.4	±	0.7	#
PHE	99.4	±	0.1	99.7	±	0.1		99.3	±	0.1	98.9	±	0.2	##
DRO	00 7		0.2	04.6		2.2		07.1		0.50	02.1		1 2	**
FRU	90.1	I	0.2	94.0	I	Z.Z		91.1	I	0.00	92.1	I	1.3	
ASP	97.3	±	0.8	96.9	±	1.0		99.2	±	0.1 #	96.6	±	1.0	
GLU	99.1	±	0.2	98.4	±	0.3		98.8	±	0.2	97.6	±	0.6	